Puma Biotechnology (PBYI) Stock Price

Puma Biotechnology Price

NASDAQ·CLOSED
8.69USD-0.22 (-2.50 %)
Market closed

Over the last 8 years Puma Biotechnology grew revenue by 30.2% annually, reaching 228.37 M USD. Earnings per share have grown at 2,300.5% per year over the last 3 years. For Puma Biotechnology, the net margin of 13.6% is up versus -11.5% a few years ago. The consensus 12-month price target for Puma Biotechnology is 5.10 USD, about 41.3% below where the stock trades today. Of 6 analysts, 0 rate the stock a buy — an overall Sell consensus. The stock trades about 100% above its 52-week low.

Puma Biotechnology stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Puma Biotechnology over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Puma Biotechnology stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Puma Biotechnology's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Puma Biotechnology Stock Price History
DatePuma Biotechnology Price
8/10/20268.69 USD
8/7/20268.91 USD
8/6/20268.12 USD
8/5/20268.04 USD
8/4/20267.68 USD
8/3/20267.69 USD
7/31/20267.93 USD
7/30/20267.89 USD
7/29/20267.82 USD
7/27/20268.12 USD
7/23/20268.01 USD
7/22/20267.87 USD
7/21/20268.58 USD
7/20/20268.30 USD
7/17/20268.53 USD
7/16/20268.40 USD
7/15/20268.41 USD
7/14/20268.28 USD
7/13/20268.07 USD
7/10/20268.00 USD
7/9/20267.90 USD
7/8/20268.06 USD
7/7/20267.96 USD
7/6/20268.29 USD
7/2/20268.26 USD
7/1/20267.99 USD
6/30/20268.11 USD
6/29/20268.19 USD
6/26/20268.11 USD
6/25/20267.67 USD
6/24/20267.95 USD
6/23/20268.04 USD
6/22/20267.66 USD
6/18/20267.34 USD
6/17/20267.24 USD
6/16/20266.99 USD
6/15/20267.18 USD
6/12/20267.20 USD
6/11/20267.10 USD
6/10/20267.15 USD
6/9/20267.05 USD
6/8/20266.85 USD
6/5/20267.03 USD
6/4/20267.01 USD
6/3/20266.81 USD
6/2/20266.98 USD
6/1/20267.12 USD
5/29/20267.17 USD
5/28/20267.24 USD
5/27/20267.31 USD
5/26/20267.27 USD
5/22/20267.08 USD
5/21/20267.05 USD
5/20/20266.99 USD
5/19/20266.81 USD
5/18/20266.81 USD
5/15/20266.92 USD
5/14/20267.19 USD
5/13/20267.17 USD
5/12/20267.08 USD
5/11/20267.14 USD
5/8/20267.49 USD
5/7/20267.26 USD
5/6/20267.45 USD
5/5/20267.35 USD
5/4/20267.53 USD
5/1/20267.49 USD
4/30/20267.51 USD
4/29/20267.48 USD
4/28/20267.54 USD
4/27/20267.51 USD
4/24/20267.54 USD
4/23/20267.53 USD
4/22/20267.43 USD
4/21/20267.26 USD
4/20/20267.37 USD
4/17/20267.47 USD
4/16/20267.24 USD
4/15/20267.48 USD
4/14/20267.57 USD
4/13/20267.57 USD
4/10/20267.78 USD
4/9/20267.80 USD
4/8/20267.51 USD
4/7/20266.97 USD
4/6/20266.89 USD
4/2/20266.90 USD
4/1/20266.76 USD
3/31/20266.39 USD
3/30/20266.13 USD
3/27/20266.08 USD
3/26/20266.27 USD
3/25/20266.33 USD
3/24/20266.26 USD
3/23/20266.25 USD
3/20/20266.12 USD
3/19/20266.15 USD
3/18/20266.00 USD
3/17/20266.14 USD
3/16/20266.07 USD
3/13/20265.90 USD
3/12/20265.88 USD
3/11/20266.00 USD
3/10/20266.06 USD
3/9/20266.22 USD
3/6/20266.05 USD
3/5/20266.23 USD
3/4/20266.40 USD
3/3/20266.21 USD
3/2/20266.42 USD
2/27/20265.70 USD
2/26/20267.60 USD
2/25/20267.68 USD
2/24/20267.49 USD
2/23/20267.11 USD
2/20/20266.83 USD
2/19/20266.79 USD
2/18/20266.68 USD
2/17/20266.75 USD
2/13/20266.82 USD
2/12/20266.80 USD
2/11/20266.64 USD
2/10/20266.61 USD
2/9/20266.88 USD
2/6/20266.94 USD
2/5/20266.79 USD
2/4/20267.10 USD
2/3/20267.10 USD
2/2/20266.82 USD
1/30/20266.48 USD
1/29/20266.43 USD
1/28/20266.32 USD
1/27/20266.57 USD
1/26/20266.43 USD
1/23/20266.42 USD
1/22/20266.86 USD
1/21/20266.89 USD
1/20/20266.60 USD
1/16/20266.37 USD
1/15/20266.38 USD
1/14/20266.42 USD
1/13/20266.24 USD
1/12/20266.28 USD
1/9/20266.11 USD
1/8/20266.20 USD
1/7/20266.09 USD
1/6/20265.86 USD
1/5/20265.94 USD
1/2/20265.77 USD
12/31/20255.95 USD
12/30/20256.01 USD
12/29/20256.09 USD
12/26/20256.16 USD
12/24/20255.96 USD
12/23/20255.91 USD
12/22/20255.83 USD
12/19/20255.63 USD
12/18/20255.62 USD
12/17/20255.58 USD
12/16/20255.67 USD
12/15/20255.82 USD
12/12/20255.86 USD
12/11/20255.73 USD
12/10/20255.59 USD
12/9/20255.52 USD
12/8/20255.40 USD
12/5/20255.30 USD
12/4/20255.29 USD
12/3/20255.19 USD
12/2/20254.87 USD
12/1/20254.96 USD
11/28/20255.05 USD
11/26/20255.05 USD
11/25/20254.95 USD
11/24/20254.98 USD
11/21/20254.89 USD
11/20/20254.84 USD
11/19/20254.89 USD
11/18/20255.06 USD
11/17/20254.96 USD
11/14/20254.89 USD
11/13/20254.95 USD
11/12/20254.99 USD
11/11/20255.19 USD
11/10/20254.73 USD
11/7/20255.99 USD
11/6/20254.90 USD
11/5/20254.95 USD
11/4/20254.90 USD
11/3/20255.04 USD
10/31/20255.10 USD
10/30/20255.46 USD
10/29/20255.16 USD
10/28/20255.25 USD
10/27/20255.27 USD
10/24/20255.23 USD
10/23/20255.04 USD
10/22/20255.23 USD
10/21/20255.17 USD
10/20/20255.45 USD
10/17/20255.47 USD
10/16/20255.41 USD
10/15/20255.50 USD
10/14/20255.31 USD
10/13/20255.29 USD
10/10/20255.12 USD
10/9/20255.21 USD
10/8/20255.23 USD
10/7/20255.18 USD
10/6/20255.03 USD
10/3/20255.13 USD
10/2/20255.22 USD
10/1/20255.27 USD
9/30/20255.31 USD
9/29/20255.05 USD
9/26/20254.84 USD
9/25/20254.70 USD
9/24/20254.72 USD
9/23/20254.71 USD
9/22/20254.46 USD
9/19/20254.42 USD
9/18/20254.52 USD
9/17/20254.34 USD
9/16/20254.52 USD
9/15/20254.64 USD
9/12/20254.47 USD
9/11/20254.50 USD
9/10/20254.54 USD
9/9/20254.71 USD
9/8/20254.56 USD
9/5/20255.03 USD
9/4/20255.11 USD
9/3/20255.13 USD
9/2/20255.11 USD
8/29/20255.04 USD
8/28/20254.97 USD
8/27/20255.10 USD
8/26/20255.18 USD
8/25/20254.99 USD
8/22/20255.25 USD
8/21/20255.22 USD
8/20/20255.11 USD
8/19/20255.09 USD
8/18/20255.01 USD
8/15/20255.73 USD
8/14/20255.32 USD
8/13/20255.30 USD
8/12/20254.87 USD
Access this data via the Eulerpool API
Get Free API Key

Puma Biotechnology Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
235.64 M USD
32.64 M USD
21.59 M USD
Jan 1, 2024
230.47 M USD
30.97 M USD
30.28 M USD
Jan 1, 2025
228.37 M USD
37.30 M USD
31.11 M USD
Jan 1, 2026 (e)
222.00 M USD
91.50 M USD
14.61 M USD
Jan 1, 2027 (e)
219.00 M USD
90.26 M USD
10.08 M USD
Jan 1, 2028 (e)
216.00 M USD
89.02 M USD
6.05 M USD
Jan 1, 2029 (e)
213.00 M USD
87.79 M USD
2.02 M USD
Jan 1, 2030 (e)
210.00 M USD
86.55 M USD
-1.51 M USD

Puma Biotechnology Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 12, 2026, 2:50 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
––27.00251.00272.00225.00253.00228.00235.00230.00228.00222.00219.00216.00213.00210.00
–––829.638.37-17.2812.44-9.883.07-2.13-0.87-2.63-1.35-1.37-1.39-1.41
––81.4886.0686.4082.2274.7075.4473.1972.1774.5674.5674.5674.5674.5674.56
170.00-1.0022.00216.00235.00185.00189.00172.00172.00166.00170.00165.53163.29161.05158.82156.58
-240.00-276.00-292.00-94.00-75.00-45.001.0012.0032.0030.0037.0091.0090.0089.0087.0086.00
––-1,081.48-37.45-27.57-20.000.405.2613.6213.0416.2340.9941.1041.2040.8540.95
-239.00-276.00-292.00-113.00-75.00-59.00-29.00–21.0030.0031.0014.0010.006.002.00-1.00
68.3115.485.80-61.30-33.63-21.33-50.85––42.863.33-54.84-28.57-40.00-66.67-150.00
32.4435.6937.5338.2039.0439.8841.0445.8148.0449.4151.5251.5251.5251.5251.5251.52
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Puma Biotechnology generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Puma Biotechnology retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Puma Biotechnology's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Puma Biotechnology has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Puma Biotechnology's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Puma Biotechnology stock margins

The Puma Biotechnology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Puma Biotechnology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Puma Biotechnology.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
74.84 %
0.51 %
-11.51 %
Jan 1, 2022
75.84 %
5.28 %
0.00 %
Jan 1, 2023
73.40 %
13.85 %
9.16 %
Jan 1, 2024
72.06 %
13.44 %
13.14 %
Jan 1, 2025
74.53 %
16.33 %
13.62 %
Jan 1, 2026 (e)
74.53 %
41.21 %
6.58 %
Jan 1, 2027 (e)
74.53 %
41.21 %
4.60 %
Jan 1, 2028 (e)
74.53 %
41.21 %
2.80 %

Puma Biotechnology Stock Revenue, EBIT, Earnings per Share

The Puma Biotechnology earnings per share therefore indicates how much revenue Puma Biotechnology has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
6.17 USD
0.03 USD
-0.71 USD
Jan 1, 2022
4.98 USD
0.26 USD
0.00 USD
Jan 1, 2023
4.91 USD
0.68 USD
0.45 USD
Jan 1, 2024
4.66 USD
0.63 USD
0.61 USD
Jan 1, 2025
4.43 USD
0.72 USD
0.60 USD
Jan 1, 2026 (e)
4.41 USD
1.78 USD
0.29 USD
Jan 1, 2027 (e)
4.35 USD
1.75 USD
0.20 USD
Jan 1, 2028 (e)
4.29 USD
1.73 USD
0.12 USD

Puma Biotechnology business model & stock analysis

Puma Biotechnology Inc. is a biopharmaceutical company based in Los Angeles. It was founded in 2010 and initially focused on the development of innovative cancer treatments. Since then, the company has significantly expanded and now offers a wide range of products and services all centered around cancer treatment. The company's business model revolves around developing drugs that address the need for novel and effective therapies to treat cancer. Puma Biotechnology Inc. is a leading player in this field and has already brought several successful products to market. One of the company's most well-known cancer treatments is Neratinib (also known as Nerlynx), which is used to treat breast cancer. Nerlynx received FDA approval in July 2017. Puma Biotechnology Inc. was founded in 2010 by Alan H. Auerbach, who had previously founded the biopharmaceutical company Cougar Biotechnology and successfully sold it to Johnson & Johnson. The history of Puma Biotechnology Inc. is marked by continuous growth. After its founding, the company acquired exclusive rights to develop neratinib for the treatment of breast cancer. The company has since conducted numerous studies and collected clinical data to prove the efficacy and safety of Nerlynx. After years of research, the medication finally received FDA approval in 2017. Puma Biotechnology Inc. has expanded its offerings since its founding and now offers a wide range of products and services centered around cancer treatment. One of the company's main areas of focus is research and development of cancer treatments. Puma Biotechnology Inc. continuously works on developing new drugs and therapies for a variety of cancer types, including breast cancer, lung cancer, and leukemia. The company is also involved in the production and marketing of pharmaceuticals. Neratinib is the company's most well-known product, but Puma Biotechnology Inc. has also brought other cancer treatments to the market. Additionally, Puma Biotechnology Inc. offers a wide range of services in the field of cancer treatment. The company is involved in the development of diagnostics and preventative measures and also offers training and consultations for doctors and patients. Nerlynx is Puma Biotechnology Inc.'s most well-known product and is now distributed worldwide. The medication is an oral therapeutic used for the adjuvant treatment of early-stage HER2-positive breast cancer in adults following adequate standard adjuvant therapy. It is taken by women who have already undergone chemotherapy, surgery, and radiation therapy. Neratinib works to prevent cancer recurrences by targeting the HER2 receptor, which normally promotes cancer cell growth. The medication blocks these receptors and can therefore inhibit tumor growth. In addition, Puma Biotechnology Inc. has also brought other products to the market, including Ribociclib, which is used in combination with other medications to treat ER-positive, HER2-negative breast cancer. In conclusion, Puma Biotechnology Inc. is a unique and emerging company with a focus on cancer treatments. Since its founding in 2010, the company has become a leading player in cancer combat. Puma Biotechnology Inc. is involved in the development of innovative therapeutic approaches, has achieved numerous medical successes, and brought many promising medications to the market. With Nerlynx, the company has introduced an effective medication for the treatment of breast cancer, and its potential is far from being realized. The company will undoubtedly play an important role in the treatment of cancer in the future.

Puma Biotechnology SWOT Analysis

Strengths

Puma Biotechnology Inc possesses several strengths that contribute to its success in the market. These strengths include:

  • Strong Research and Development Capabilities: Puma Biotechnology is known for its robust R&D capabilities, allowing it to develop innovative and effective oncology drugs.
  • Specialization in Oncology Therapeutics: The company's focus on oncology therapeutics enables Puma Biotechnology to gain in-depth knowledge and expertise in this specific field.
  • Strategic Partnerships: Puma Biotechnology has established strategic collaborations with renowned academic institutions and industry leaders, fostering knowledge sharing and enhancing its market position.
  • Strong Intellectual Property Portfolio: The company holds a significant number of patents, protecting its innovative products from competitors and ensuring a competitive edge in the market.

Weaknesses

Despite its strengths, Puma Biotechnology Inc also faces certain weaknesses that may pose challenges to its growth and competitiveness. These weaknesses include:

  • Dependency on a Single Product: Puma Biotechnology heavily relies on its flagship product, which exposes the company to significant risks in case of any issues or market fluctuations related to that specific product.
  • Limited Product Portfolio: The company's product line is relatively limited, which restricts its ability to generate diverse revenue streams and increases vulnerability to market dynamics.
  • High Research and Development Costs: Developing new oncology therapeutics involves substantial expenses, and Puma Biotechnology may face financial challenges in sustaining its R&D efforts.
  • Regulatory Challenges: The company operates in a highly regulated industry, and obtaining necessary approvals for new products can be a time-consuming and costly process.

Opportunities

There are several opportunities present in the market that Puma Biotechnology Inc can capitalize on. These opportunities include:

  • Expanding Global Oncology Market: The increasing prevalence of cancer worldwide opens doors for Puma Biotechnology to expand its market reach and address the growing demand for effective therapies.
  • Mergers and Acquisitions: Strategic acquisitions or partnerships with other biopharmaceutical companies can provide Puma Biotechnology with access to complementary technology and intellectual property.
  • Advancements in Precision Medicine: The advancements in precision medicine and personalized treatments create opportunities for Puma Biotechnology to develop targeted therapies, offering improved outcomes for patients.
  • Emerging Markets: Expanding into emerging markets, where access to oncology therapeutics is limited, presents a significant growth avenue for Puma Biotechnology.

Threats

Puma Biotechnology Inc faces certain threats that could impact its business operations and market position. These threats include:

  • Intense Competition: The biopharmaceutical industry is highly competitive, with many established players and emerging startups, intensifying the challenge for market share and profitability.
  • Pricing Pressure: Pricing pressures from government regulations, payers, and competitors can affect Puma Biotechnology's ability to maintain optimal pricing for its products, potentially impacting revenues.
  • Patent Expirations: As patents expire, Puma Biotechnology's products may face generic competition, reducing market share and profitability.
  • Uncertainty in Regulatory Landscape: Changes in regulations and policies related to drug approvals and reimbursements can introduce uncertainty and impact the company's ability to successfully navigate the market.

Puma Biotechnology Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Puma Biotechnology Employees
Details
Date
Puma Biotechnology Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Puma Biotechnology Segments

Puma Biotechnology Revenue by Segment (1/3)

  • 3 Years

  • Max

Product
License
Royalty
Details
Date
Product
License
Royalty
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
200.02 M USD
0.00 USD
28.01 M USD
Jan 1, 2023
203.11 M USD
0.00 USD
32.53 M USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
204.07 M USD
0.00 USD
24.30 M USD

Puma Biotechnology Revenue by Segment (2/3)

  • 3 Years

  • 5 Years

  • Max

Product
Product Revenue, Net
License
Royalty
Royalty Revenue
License Revenue
Details
Date
Product
Product Revenue, Net
License
Royalty
Royalty Revenue
License Revenue
Jan 1, 2018
0.00 USD
200.49 M USD
0.00 USD
0.00 USD
0.00 USD
50.50 M USD
Jan 1, 2019
0.00 USD
211.62 M USD
0.00 USD
0.00 USD
391,000.00 USD
60.25 M USD
Jan 1, 2020
0.00 USD
196.73 M USD
0.00 USD
0.00 USD
5.68 M USD
1.00 M USD
Jan 1, 2021
189.06 M USD
0.00 USD
51.75 M USD
12.34 M USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Puma Biotechnology Revenue by Segment (3/3)

  • Max

Product
Royalty
Details
Date
Product
Royalty
Jan 1, 2018
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
Jan 1, 2024
195.19 M USD
35.28 M USD
Jan 1, 2025
0.00 USD
0.00 USD

Puma Biotechnology Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Puma Biotechnology historical P/E ratio, EBIT multiple, and P/S ratio

Puma Biotechnology annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Puma Biotechnology shares outstanding

The number of shares of Puma Biotechnology was 51.52 M in 2025. This indicates how many shares Puma Biotechnology is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
41.04 M Stocks
Jan 1, 2022
45.81 M Stocks
Jan 1, 2023
48.04 M Stocks
Jan 1, 2024
49.41 M Stocks
Jan 1, 2025
51.52 M Stocks
Jan 1, 2026 (e)
51.52 M Stocks
Jan 1, 2027 (e)
51.52 M Stocks
Jan 1, 2028 (e)
51.52 M Stocks

Current Puma Biotechnology forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
42.86 %
Buy
0.00 % (0)
Hold
50.00 % (3)
Sell
50.00 % (3)
12M Price Target
5.10
Last Price
8.69
Currency
USD
12M Return Potential
-41.31 %
LTM Return
0 %

Puma Biotechnology Analyst Rating Actions

DateFirmActionRatingReliability
2/28/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
12/23/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
11/20/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
11/8/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
8/2/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
7/26/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
6/4/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
6/3/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
5/20/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
5/3/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Puma Biotechnology Earnings Calls

2025

Puma Biotechnology Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/5/20260.04USD-54.06 MUSD-2026 Q2
5/7/2026-0.13USD-42.84 MUSD-2026 Q1
2/26/20260.23USD-69.97 MUSD-2025 Q4
5/2/2024-USD-57.63 MUSD-2024 Q1
2/29/20240.31USD-75.02 MUSD-2023 Q4
8/2/2023-0.07USD-53.79 MUSD-2023 Q2
5/3/2023-0.09USD-51.76 MUSD-2023 Q1
3/1/20230.05USD-57.92 MUSD-2022 Q4
11/3/2022-0.06USD-51.22 MUSD-2022 Q3
8/4/20220.01USD-53.41 MUSD-2022 Q2

EESG©

Eulerpool ESG Scorecard© for the Puma Biotechnology stock

42/100
47
Environment
29
Social
50
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees50
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Puma Biotechnology shareholder structure

% Name
13.69084%
Auerbach (Alan H)
Auerbach (Alan H)
8.19865%
Acorn Capital Advisors, LLC
Acorn Capital Advisors, LLC
7.35553%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
5.95334%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
3.98521%
Acadian Asset Management LLC
Acadian Asset Management LLC
3.72041%
Renaissance Technologies LLC
Renaissance Technologies LLC
...

Puma Biotechnology Beneficial Ownership Filings (SEC 13D/G)

Free Float
76.4%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
11.00%
Oleg Nodelman
Oleg Nodelman
SEC ↗
11.00%
EcoR1 Capital, LLC
EcoR1 Capital, LLC
SEC ↗
11.00%
EcoR1 Capital Fund Qualified, L.P.
EcoR1 Capital Fund Qualified, L.P.
SEC ↗
9.00%
The Vanguard Group - 23-1945930
The Vanguard Group - 23-1945930
SEC ↗
8.59%
Alger Group Holdings, LLC
Alger Group Holdings, LLC
SEC ↗
8.59%
Alger Associates, Inc. 13-3017981
Alger Associates, Inc. 13-3017981
SEC ↗
7.80%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
6.43%
Wellington Management Group LLP
Wellington Management Group LLP
SEC ↗
6.40%
(1)Names of reporting persons. BlackRock, Inc.
(1)Names of reporting persons. BlackRock, Inc.
SEC ↗
6.18%
Harris Financial Corp
Harris Financial Corp
SEC ↗

Puma Biotechnology Executives and Management Board

11 members · avg. age 61 · 18 % women

AA

Mr. Alan Auerbach (55)

Chairman of the Board, President, Chief Executive Officer, Secretary · since 2010

3.97 M USD

Management

MN

Mr. Maximo Nougues (56)

Chief Financial Officer

1.40 M USD
DH

Mr. Douglas Hunt (60)

Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance, and Law Officer

1.22 M USD
MO

Mr. Mariann Ohanesian

Investor Relations · since 2016

–

Board of Directors

JM

Mr. Jay Moyes (71)

Lead Independent Director

160,930.00 USD
TW

Dr. Troy Wilson (56)

Independent Director

160,930.00 USD
BS

Mr. Brian Stuglik (66)

Independent Director

155,930.00 USD
AS

Dr. Adrian Senderowicz (61)

Independent Director

153,430.00 USD
MM

Mr. Michael Miller (68)

Independent Director

145,930.00 USD
AD

Ms. Allison Dorval (49)

Independent Director

143,430.00 USD

Puma Biotechnology Supply Chain

Puma Biotechnology Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
10 companies
#NameTrend
1
Knight Therapeutics
Supplier·Customer·Pharmaceuticals·CA
-0.23
0.46
0.37
-0.15
-0.26
0.31
#NameTrend
1
Pfizer
Supplier·Customer·Pharmaceuticals·US
-0.08
0.86
0.20
0.13
-0.79
-0.89
2
UnitedHealth Group
Customer·Health Care Providers & Services·US
-0.02
0.76
0.59
0.32
-0.84
-0.88
3
McKesson
Customer·Health Care Providers & Services·US
0.05
-0.70
-0.37
-0.40
-0.81
-0.85
4
CVS Health
Customer·Health Care Providers & Services·US
-0.71
0.36
0.52
-0.39
-0.85
-0.85
5
Centene
Customer·Health Care Providers & Services·US
0.19
-0.10
0.55
0.12
-0.74
-0.83

Frequently asked questions about Puma Biotechnology

The business model of Puma Biotechnology Inc. is focused on developing and commercializing innovative treatments for cancer. The company specializes in the research and development of targeted therapies that aim to address specific types of cancer, such as HER2-positive breast cancer. Puma Biotechnology Inc. is committed to advancing the field of oncology through the discovery and development of effective and safe medications. By utilizing its expertise in molecular biology and drug development, the company aims to improve patient outcomes and contribute to the fight against cancer. Puma Biotechnology Inc. strives to create value for its shareholders by bringing novel treatments to market and maintaining a strong pipeline of innovative therapies.

Puma Biotechnology Inc is primarily active in the biotechnology industry.

The main competitors of Puma Biotechnology Inc in the market include well-established pharmaceutical companies such as Pfizer, Novartis, and Roche. These companies also focus on developing and commercializing innovative treatments for various diseases, including cancer. Puma Biotechnology Inc faces competition in its targeted therapy segment, particularly in the field of HER2-positive breast cancer treatment, where these competitors have their own competing products. However, Puma Biotechnology Inc's unique drug development pipeline and its focus on personalized medicine allow it to differentiate itself in the market.

Puma Biotechnology Inc. is a renowned biopharmaceutical company with a rich history and background. Established in 2010, Puma Biotechnology primarily focuses on the development and commercialization of innovative therapeutics to treat various forms of cancer. Headquartered in Los Angeles, California, the company has successfully developed and received approvals for its flagship product, Nerlynx (neratinib), which is utilized in the treatment of HER2-positive breast cancer. Recognized for its cutting-edge research and development efforts, Puma Biotechnology strives to provide advanced treatment options and improve the lives of cancer patients worldwide. With a commitment to pioneering medical breakthroughs, Puma Biotechnology continues to leave a significant impact in the field of oncology.

Puma Biotechnology Inc has achieved several significant milestones. One of the notable achievements includes the successful development and commercialization of Nerlynx (neratinib), an FDA-approved treatment for HER2-positive breast cancer. Additionally, Puma Biotechnology Inc has made substantial progress in conducting clinical trials and expanding the indications for Nerlynx. The company has also advanced its research pipeline, collaborating with leading institutions to explore potential therapies for various types of cancer. Puma Biotechnology Inc's commitment to innovation and patient-centric approach has positioned them as a key player in the biotechnology industry.

Puma Biotechnology Inc is primarily present in the United States.

Puma Biotechnology Inc represents a strong commitment to improving the lives of patients battling cancer. The company's corporate philosophy centers around advancing innovative treatments and therapies to combat various forms of cancer. Puma Biotechnology is dedicated to conducting rigorous research and development to bring effective, cutting-edge medicines to market. With a focus on personalized medicine, Puma Biotechnology strives to tailor treatments to patients' specific needs, enhancing their chances of positive outcomes. By harnessing scientific advancements and collaborating with leading experts, Puma Biotechnology remains steadfast in its mission to make a meaningful impact in the fight against cancer.

Analysts currently set an average price target of 5.10 USD for the Puma Biotechnology stock (median: 5.10 USD), implying -41.3 % versus the latest price. The consensus is based on 6 analyst ratings.

Puma Biotechnology Analyst Price Targets 2026

6 analysts currently rate the Puma Biotechnology stock: 0 recommend buying, 3 holding and 3 selling. For 2026, analysts expect Puma Biotechnology to generate revenue of 222.00 M USD and earnings per share of 0.28 USD.

Puma Biotechnology Analyst Price Targets 2026

Converted at the current exchange rate, the Puma Biotechnology share trades at 7.53 EUR (8.69 USD).

The Puma Biotechnology share (PBYI) is listed on 1 stock exchanges, including: NASDAQ (PBYI).

Puma Biotechnology Inc is an American biotech company that focuses on the development of innovative cancer therapies. It was founded in 2010 and is headquartered in Los Angeles, California. Puma Biotechnology operates in two business segments: drug development and commercialization of drugs. The primary business unit focuses on the development of cancer drugs. The flagship product of Puma Biotechnology is Neratinib, an oral cancer medication used for the treatment of HER2-positive breast cancer. Other clinical studies are also underway, including PB272, another oral cancer medication for the treatment of HER2-positive breast cancer and other types of cancer. In addition to drug development, Puma Biotechnology also engages in the commercialization of drugs, marketing Neratinib in the US, Europe, and Asia in collaboration with various partners. The company works closely with medical communities and patient organizations to raise awareness of the latest treatment options and increase the availability of medications in different countries. Puma Biotechnology also collaborates with scientific and clinical organizations to advance the development of innovative cancer therapies. The company aims to develop and bring to market patient-centric cancer therapies that can improve the quality of life for cancer patients. Puma Biotechnology plans to increase its research and development activities, expand its product range to cover more types of cancer, and expand into new markets while increasing production capacity to meet higher demand for its products. Overall, Puma Biotechnology Inc has a strong business model based on successful development of cancer medications and a strong commercial presence. The company's future prospects are promising as it focuses on the direct needs of cancer patients and strives to develop innovative therapies that have the potential to improve the lives of millions of patients worldwide.

The expected revenue of Puma Biotechnology is 222.00 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Puma Biotechnology is 14.61 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Puma Biotechnology is currently 30.64. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Puma Biotechnology stock.

The price-to-sales ratio (P/S) of Puma Biotechnology is currently 2.02. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Puma Biotechnology stock.

The Eulerpool Quality Score for Puma Biotechnology is 5/10.

The ISIN of Puma Biotechnology is US74587V1070. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Puma Biotechnology is A1J643. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Puma Biotechnology is PBYI. The ticker symbol is used to trade Puma Biotechnology shares on the stock exchange.

Puma Biotechnology paid dividends every year for the past 0 years.

Puma Biotechnology is assigned to the 'Health' sector.

The dividends of Puma Biotechnology are distributed in USD.

All fundamentals and in-depth analysis of Puma Biotechnology

Our stock analysis for Puma Biotechnology stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Puma Biotechnology. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Puma Biotechnology Stock
Puma Biotechnology Revenue→
Puma Biotechnology Stock
Puma Biotechnology Net Income→
Puma Biotechnology Stock
Puma Biotechnology P/E→
Puma Biotechnology Stock
Puma Biotechnology P/S→
Puma Biotechnology Stock
Puma Biotechnology EBIT→
Puma Biotechnology Stock
Puma Biotechnology Dividend→
Puma Biotechnology Stock
Puma Biotechnology Directors Dealings→
Puma Biotechnology Stock
Puma Biotechnology Stocks→
Puma Biotechnology Stock
Puma Biotechnology Market capitalization→
Puma Biotechnology Stock
Puma Biotechnology Debt→
Puma Biotechnology Stock
Puma Biotechnology Liabilities→
Puma Biotechnology Stock
Puma Biotechnology Equity→
Puma Biotechnology Stock
Puma Biotechnology AAQS→
Puma Biotechnology Stock
Puma Biotechnology Employees→
Puma Biotechnology Stock
Puma Biotechnology ROE→
Puma Biotechnology Stock
Puma Biotechnology ROA→
Puma Biotechnology Stock
Puma Biotechnology ROCE→
Puma Biotechnology Stock
Puma Biotechnology News→
Puma Biotechnology Stock
Puma Biotechnology Analyst Price Targets→

Health Stocks

PuraPharm CorpPulsenmorePure BiologicsPulse BiosciencesPuriblood Medical CoPulmonxPW Medtech GroupPulmatrixPYC TherapeuticsPulike Biological EngineeringPyridam Farma Tbk PTPTC TherapeuticsAll Stocks A–Z →